Contraindicated in:
Use Cautiously in:
GI: diarrhea, nausea, upper abdominal pain, vomiting.
Metab: weight loss.
Neuro: depression, headache.
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA).
Drug-Drug:
Renal Impairment
Therapeutic Classification: antirheumatics, antipsoriatics
Pharmacologic Classification: phosphodiesterase type 4 inhibitors
Absorption: 73% absorbed following oral administration.
Distribution: Unknown.
Metabolism/Excretion: Extensively metabolized (mostly by CYP3A4); metabolites are not pharmacologically active. Excreted in urine (58%) and feces (39%) as inactive metabolites; 3% excreted unchanged in urine, 7% in feces.
Half-life: 69 hr.
(blood levels)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | unknown | 2.5 hr | 1224 hr |
Improvement in joint symptoms make take up to 4 mos.
NDC Code*